Accelerating Discovery Success with Structure-Guided Drug Design

DATE

September 26, 2024

TIME

8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST - Duration: 60 Minutes

Overview

The first challenge in drug discovery is selecting a biological target and validating a “druggable” binding site. The key to this is identifying several potent compounds that can be used in more advanced validating assays. To achieve this go/no-go point, suitable chemical starting points need to be found and then, compounds optimized for binding. We have found that protein X-ray crystallography is essential to accelerate the design process by providing a level of structural detail that is unmatched using only computational methods.

Artemis was an unproven target to block DNA-repair in oncology. Progress was slow due to difficulties in protein production, lead chemical matter and lack of experimental protein structures. Curia’s team designed a new protein construct that provided the first crystal structure of Artemis. A unique screening library produced novel hits to an allosteric binding site. The structural biology team co-crystallized several new series in Artemis and ultimately, more than 80 co-crystal structures were provided.

Using collaborative efforts of medicinal and computational chemistry, a structure-driven SAR development provided a 450 fold improvement in IC50’s to this novel binding site. Without these structures, key induced-fit effects could not have been predicted.

Key Learning Objectives:

Accelerating the design of low nanomolar compounds is essential in target validation.
The structure-driven SAR process requires excellent structural biology, medicinal and computational integration.

Who Should Attend:

Medicinal chemists
Computational chemists
Chemical biologists
Structural biologists

Brought to you by:

Speakers

Mary Rosenblum
Senior Research Scientist I,
Curia Global, Inc.

Douglas B. Kitchen
PhD, Research Fellow,
Curia Global, Inc.

Melissa O'Meara
Forensic Science Consultant,
C&EN Media Group

Registration

Forwarded this event? Clear the form

Work Email Address*

Salutation

First Name*

Last Name*

Company*

Address 1*

State*

Country/Territory/Area*

Business Phone

Are you currently involved in a drug discovery project? *

Would you be open to discussing potential collaborations or solutions for your early drug discovery challenges after the webinar? *

I would like to receive C&EN’s weekly newsletter with the latest in chemistry news

I would like to receive more information on products and services from the American Chemical Society

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

View On Demand Webinars